Teva Pharma (TEVA) PT Lowered to $64 at Mizuho; 'Buy' Maintained
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
Mizuho Securities analyst Irina Koffler lowered her price target on Teva Pharma (NYSE: TEVA) price to $64.00 (from $70.00) following a negative IPR decision on two Copaxone patents but maintained a Buy rating. The analyst has gotten more conservative in their outer year expectations.
Koffler commented, "Our Buy thesis is predicated on valuation rather than any particular catalyst, though additional visibility into the recently acquired generics business and pipeline could serve to drive share momentum in 2H:16."
Shares of Teva Pharma closed at $51.63 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alibaba (BABA) PT Raised to $148 at Deutsche Bank
- Sanchez Energy (SN) PT Raised to $16 at FBR Capital; Reiterates Outperform
- Zions Bancorp (ZION) PT Lowered to $49 at FIG Partners Following 4Q EPS Beat
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst PT Change
Related EntitiesIrina Koffler
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!